Fate Therapeutics (NASDAQ:FATE – Get Rating) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday. Other research analysts have also recently issued reports about the company. BMO Capital Markets cut Fate Therapeutics from an “outperform” rating to a “market perform” rating and lowered […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 21,580,000 shares, a growth of 15.6% from the February 28th total of 18,660,000 shares. Based on an average daily trading volume, of 4,010,000 shares, […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) has been assigned an average recommendation of “Hold” from the twenty-three brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company. The […]
StockNews.com upgraded shares of Fate Therapeutics (NASDAQ:FATE – Get Rating) from a sell rating to a hold rating in a research report released on Monday. Other equities research analysts also recently issued reports about the stock. SVB Leerink dropped their price objective on shares of Fate Therapeutics from $62.00 to $10.00 and set an outperform […]